Exome Asset Management’s Replimune Group REPL Stock Holding History

Exome Asset Management’s Portfolio REPL Stock Details REPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-73,614	Closed	-$308K	–	84
2025 Q3	$308K	Sell	73,614 -324,232	-81%	-$2.07M	0.19%	65
2025 Q2	$3.7M	Buy	397,846 +103,000	+35%	+$899K	2.75%	10
2025 Q1	$2.87M	Buy	294,846 +240,108	+439%	+$2.97M	2.56%	16
2024 Q4	$663K	Buy	+54,738	New	+$665K	0.5%	50

Other funds holding REPL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Exome Asset Management's REPL Position: Q4 2025 in Review

Exome Asset Management sold out of Replimune Group (REPL) in Q4 2025, closing a stake of 73,614 shares — an estimated $308K sold.

Exome Asset Management first reported a position in REPL in Q4 2024 and held it in 4 quarters. The position peaked at $3.7M in Q2 2025. 164 funds tracked by Wall St. Rank hold REPL as of Q4 2025.

Exome Asset Management reported no remaining Replimune Group position as of Q4 2025 after selling out during the quarter.
Exome Asset Management sold 73,614 Replimune Group shares in Q4 2025, an estimated $308K.
Exome Asset Management first reported a position in Replimune Group in Q4 2024 and held it in 4 quarters.
Exome Asset Management's Replimune Group position peaked at $3.7M in Q2 2025.
164 funds tracked by Wall St. Rank held Replimune Group as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.